Table 1.
Patient characteristics at baseline (n = 443)
| Characteristics (n = 443) | N (%) |
|---|---|
| Age, years | |
| Range | 18–70 |
| Median | 36 |
| Age category | |
| ≤ 35 years | 211 |
| > 35 years | 232 |
| Time from diagnosis | |
| ≤ 3 months | 329 (74) |
| > 3–≤ 6 months | 43 (10) |
| > 6 months–≤ 12 months | 26 (6) |
| > 12 months | 45 (10) |
| Male:female | 301:142 |
| Use of non-TKI medicationsa | 162 (37) |
| Sokal risk category | |
| Low | 97 (22) |
| Intermediate | 206 (47) |
| High | 140 (32) |
| Hasford risk category | |
| Low | 192 (43) |
| Intermediate | 191 (43) |
| High | 60 (14) |
| EUTOS risk category | |
| Low | 379 (86) |
| High | 64 (14) |
aPrior therapy given for at > 1 month prior to start of imatinib—153 received hydroxyurea, 11 received busulfan and 5 received interferon